Developing novel long-acting therapeutics targeting chronic cardiometabolic diseases.
Antlia Bioscience, Inc. has raised $6.0M in total funding. The most recent round was Seed.
Antlia Bioscience, Inc. is headquartered in Encinitas, CA.
Developing novel long-acting therapeutics targeting chronic cardiometabolic diseases.
Antlia Bioscience develops novel long-acting therapeutics targeting chronic cardiometabolic diseases.
Founded in 2020 by Brian Johnson and Nigel Shankley, the San Diego biopharma has raised roughly $6.2M developing long-acting peptide therapies for cardiometabolic disease.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.